Jamet P, Blanc L, Fayne O C, Traore I, Bobin P
Institut Marchoux, Bamako, Mali.
Int J Lepr Other Mycobact Dis. 1994 Jun;62(2):209-14.
Between 1982 and 1985, a single 1500 mg dose of rifampin (RMP) was given to 136 multibacillary leprosy patients who had become clinically inactive and skin-smear negative after various durations of dapsone monotherapy, and then antileprosy chemotherapy was totally stopped. By the end of June 1992, 15 relapses were detected among these patients. The overall relapse rate was 11%; the relapse rate per 100 patient-years was 2.1%, which was the highest among those published to date; the cumulative risk of relapse at year 7 of follow up was 8.8%. All of these figures indicate that the relapse rate among this group was at least the same as in other studies where patients received dapsone monotherapy only. Therefore, the administration of a single large dose of RMP could neither prevent relapse nor reduce its rate among multibacillary patients who had already become clinically and skin-smear negative after dapsone monotherapy.
1982年至1985年间，对136例多菌型麻风患者给予单次1500毫克利福平（RMP），这些患者在接受不同疗程的氨苯砜单药治疗后临床症状已不活跃且皮肤涂片呈阴性，随后完全停止抗麻风化疗。到1992年6月底，在这些患者中检测到15例复发。总体复发率为11%；每100患者年的复发率为2.1%，这是迄今为止已发表研究中最高的；随访第7年的累积复发风险为8.8%。所有这些数据表明，该组患者的复发率至少与其他仅接受氨苯砜单药治疗的研究相同。因此，对于在氨苯砜单药治疗后已临床症状不活跃且皮肤涂片呈阴性的多菌型患者，给予单次大剂量RMP既不能预防复发，也不能降低其复发率。
